Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.45 |
| ▸ | HINT1 | P49773 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 6/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22883494 | 0.85 | TLR7 (0.42) | ALDH1A1TLR7PNP | |
| SCHEMBL22883248 | 0.84 | KDM4E (0.42) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL7257443 | 0.83 | HINT1 (0.54) | ALDH1A1TLR7HINT1PNPGSK3A | |
| SCHEMBL18759054 | 0.83 | HINT1 (0.54) | ALDH1A1TLR7HINT1PNPGSK3A | |
| SCHEMBL23202292 | 0.80 | TLR7 (0.49) | ALDH1A1TLR7HINT1GSK3ARPS6KA3 | |
| SCHEMBL12112070 | 0.80 | TLR7 (0.69) | TLR7 | |
| SCHEMBL10183060 | 0.80 | TLR7 (0.69) | TLR7 | |
| SCHEMBL17198375 | 0.78 | ALDH1A1 (0.56) | ALDH1A1HINT1PNPGSK3ARPS6KA3 | |
| SCHEMBL23202283 | 0.77 | ALDH1A1 (0.48) | ALDH1A1TLR7HINT1PNPGSK3A | |
| SCHEMBL25711923 | 0.75 | HINT1 (0.50) | TLR7HINT1GSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | ALDH1A1 4671/4885TLR7 37/4885HINT1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.